Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 2669279 | HLA (HLA) | transplantation | NA | NA | NA | unclassified | |
| this mechanism, which involves helper t cells interacting with class ii hla, may distinguish transplantation-associated arteriosclerosis from typical acute rejection, which may involve primarily cytolytic t cells interacting with class i hla. | |||||||
| 2669279 | HLA (HLA) | arteriosclerosis | NA | NA | NA | unclassified | |
| this mechanism, which involves helper t cells interacting with class ii hla, may distinguish transplantation-associated arteriosclerosis from typical acute rejection, which may involve primarily cytolytic t cells interacting with class i hla. | |||||||
| 2671729 | HLA-DR (HLA-DR) | transplantation | NA | NA | NA | unclassified | |
| in view of the increased rate of sensitization and the lack of improvement in graft survival, the transfusion of blood mismatched for two hla-dr antigens appears to be contraindicated in candidates for transplantation. | |||||||
| 2671729 | HLA-DR (HLA-DR) | renal transplantation | NA | NA | NA | unclassified | |
| among recipients of transfusions who shared one hla-dr antigen with their respective donors, antibodies developed in 6 of 28 who had received one transfusion, in 2 of 16 who had received three transfusions, and in 4 of 24 who had undergone renal transplantation. | |||||||
| 2676032 | NA (NA) | transplantation | NA | NA | NA | unclassified | |
| in non-hla matched transplantation, donor-specific transfusion, as well as immunosuppressives, may exert some benefit in graft survival. | |||||||
| 2676560 | HLA-A*02 | transplantation | NA | NA | NA | unclassified | |
| to determine the specificity of circulating hiv-immune ctl in humans, a panel of doubly transfected mouse p815 tumor cells was produced which express the human hla-a2 or hla-a3 transplantation antigen gene and one hiv-1 gene (env, gag or nef). | |||||||
| 2676560 | HLA-A*02 | tumor | NA | NA | NA | unclassified | |
| to determine the specificity of circulating hiv-immune ctl in humans, a panel of doubly transfected mouse p815 tumor cells was produced which express the human hla-a2 or hla-a3 transplantation antigen gene and one hiv-1 gene (env, gag or nef). | |||||||
| 2676560 | HLA-A*03 | transplantation | NA | NA | NA | unclassified | |
| to determine the specificity of circulating hiv-immune ctl in humans, a panel of doubly transfected mouse p815 tumor cells was produced which express the human hla-a2 or hla-a3 transplantation antigen gene and one hiv-1 gene (env, gag or nef). | |||||||
| 2676560 | HLA-A*03 | tumor | NA | NA | NA | unclassified | |
| to determine the specificity of circulating hiv-immune ctl in humans, a panel of doubly transfected mouse p815 tumor cells was produced which express the human hla-a2 or hla-a3 transplantation antigen gene and one hiv-1 gene (env, gag or nef). | |||||||
| 2684259 | HLA (HLA) | transplantation | NA | cyclophosphamide | NA | unclassified | |
| all patients received marrow from an hla identical sibling after preparation with cyclophosphamide 120 mg/kg and total body irradiation (tbi) 330 cgy on each of the three days prior to transplantation. | |||||||
Copyright 2024